Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.30 |
| ▸ | RET | P07949 | 2/20 | 0.30 |
| ▸ | IGF1R | P08069 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 2/20 | 0.30 |
| ▸ | CLK2 | P49760 | 2/20 | 0.30 |
| ▸ | GSK3A | P49840 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | PRKX | P51817 | 2/20 | 0.30 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.30 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.30 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411251 | 1.00 | CSNK2A1 (0.33) | CSNK2A1DPP4MAPTAURKADAPK3 | |
| SCHEMBL2526551 | 0.79 | PARP1 (0.32) | CSNK2A1DYRK1APARP1 | |
| SCHEMBL37383 | 0.79 | XDH (0.38) | CSNK2A1DPP4AURKADAPK3PRKD3 | |
| SCHEMBL29354230 | 0.79 | XDH (0.38) | CSNK2A1DPP4AURKADAPK3PRKD3 | |
| Hydrochloric Acid SCHEMBL4763242 | 0.78 | XDH (0.37) | CSNK2A1DPP4AURKADAPK3PRKD3 | |
| SCHEMBL11456966 | 0.78 | XDH (0.37) | CSNK2A1DPP4AURKADAPK3PRKD3 | |
| SCHEMBL2352412 | 0.76 | CSNK2A1 (0.41) | CSNK2A1DPP4AURKADAPK3PRKD3 | |
| 6-Chloroguanine SCHEMBL6711 | 0.76 | DPP4 (0.52) | CSNK2A1DPP4AURKADAPK3PRKD3 | |
| SCHEMBL16146681 | 0.76 | LMNA (0.33) | PARP1 | |
| SCHEMBL2997391 | 0.76 | CSNK2A1 (0.36) | CSNK2A1DPP4MAPTAURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 570 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | claimed |
| CN-117467726-A | Preparation method of purine nucleoside | 天津凯莱英生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| US-9408848-B2 | Fluorescent CDK inhibitors for treatment of cancer | GEORGETOWN UNIVERSITY (US) | 2016-08-09 | — | — | US | claimed |
| CN-102391356-B | Steroid n-glycoside analogue taking dihydro-pyranoid ring as D ring and preparation and application thereof | UNIV ZHENGZHOU | 2013-05-01 | — | — | CN | claimed |
| CN-102659785-A | 2-amino-6-aminomethylpurine compound and preparation method and application thereof | UNIV SHANDONG | 2012-09-12 | — | — | CN | claimed |
| CN-102391356-A | Steroid n-glycoside analogue taking dihydro-pyranoid ring as D ring and preparation and application thereof | UNIV ZHENGZHOU | 2012-03-28 | — | — | CN | claimed |
| US-20110269178-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | claimed |
| EP-2330908-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | Georgetown University (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010019967-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | claimed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | claimed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | claimed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| EP-4178959-B1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2025-09-10 | — | — | EP | disclosed |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | disclosed |
| US-12391694-B2 | Process for the preparation of 2-fluoroadenine | MERCK SHARP & DOHME LLC | 2025-08-19 | — | — | US | disclosed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | UNIVERSITY OF WINDSOR (CA) | 2025-03-13 | — | — | US | disclosed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240261317-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASEUSING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | ROME THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | disclosed |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-07-25 | — | — | US | disclosed |
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-12012408-B2 | Purine compounds and method for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2024-06-18 | — | — | US | disclosed |
| CN-118165044-A | Stereoselective synthesis method and application of alpha-2' -deoxynucleoside | 中国药科大学 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024105159-A1 | LIGANDS OF THE M6A-RNA READERS | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| CN-115611867-B | (1, 1-Trichloro-2) carbamate derivative and preparation method and application thereof | 中南大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117467726-B | Preparation method of purine nucleoside | 天津凯莱英生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-112204010-B | Heterocyclic derivatives and uses thereof | C&C新药研究所 | 2024-03-19 | — | — | CN | disclosed |
| CN-117467726-A | Preparation method of purine nucleoside | 天津凯莱英生物科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117448850-A | Universal method for preparing polyfluoro biaryl compound without transition metal | 中国科学院理化技术研究所 | 2024-01-26 | — | — | CN | disclosed |
| US-11851436-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3814354-B1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2023-11-08 | — | — | EP | disclosed |
| EP-3814354-B1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2023-11-08 | — | — | EP | disclosed |
| CN-116813621-A | 9H purine compounds, pharmaceutical composition and application thereof | 江南大学 | 2023-09-29 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3941476-B1 | ROSCOVITINE ANALOGUES AND USE THEREOF FOR TREATING RARE BILIARY DISEASES | UNIV SORBONNE (FR) | 2023-05-31 | — | — | EP | disclosed |
| EP-4178959-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2023-05-17 | — | — | EP | disclosed |
| US-20230104823-A1 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | CYCLACEL LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230029430-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2023-01-26 | — | — | US | disclosed |
| CN-111606891-B | (1,1,1-trichloro-2) carbamate derivative and preparation method and application thereof | 中南大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-115611867-A | (1, 1-trichloro-2) carbamate derivatives, and preparation method and application thereof | 中南大学 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022245814-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-115337309-A | Carbocyclic nucleoside derivative and antiviral application thereof | 陈昊 | 2022-11-15 | — | — | CN | disclosed |
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS AG (CH) | 2022-10-25 | — | — | US | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022178256-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220265637-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2022-08-25 | — | — | US | disclosed |
| US-20220242866-A1 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE | MERCK SHARP & DOHME CORP. (US) | 2022-08-04 | — | — | US | disclosed |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20220160716-A1 | ROSCOVITINE ANALOGUES AND USE THEREOF FOR TREATING RARE BILIARY DISEASES | SORBONNE UNIVERSITE (FR) | 2022-05-26 | — | — | US | disclosed |
| US-20220160716-A1 | ROSCOVITINE ANALOGUES AND USE THEREOF FOR TREATING RARE BILIARY DISEASES | SORBONNE UNIVERSITE (FR) | 2022-05-26 | — | — | US | disclosed |
| CN-112574217-B | Acyclic nucleoside lead compound, preparation method thereof and application thereof in pharmacy | 河南师范大学 | 2022-05-20 | — | — | CN | disclosed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3941476-A2 | ROSCOVITINE ANALOGUES AND USE THEREOF FOR TREATING RARE BILIARY DISEASES | SORBONNE UNIVERSITE (FR) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2022012702-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2022-01-20 | — | — | WO | disclosed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113795493-A | Roscovitine analogs and their use for treating rare biliary disorders | 索邦大学 | 2021-12-14 | — | — | CN | disclosed |
| CN-109912599-B | Chemical entities, compositions, and methods | 英特利凯恩有限责任公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| CN-113444113-A | Artemisinin-base split compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application | 贵州大学 | 2021-09-28 | — | — | CN | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| CN-110283174-B | PI3K delta inhibitor and application thereof | 安徽中医药大学 | 2021-07-23 | — | — | CN | disclosed |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210171524-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20210171524-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2021-06-10 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3814354-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2021-05-05 | — | — | EP | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3802495-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-14 | — | — | EP | disclosed |
| CN-112574217-A | Acyclic nucleoside lead compound, preparation method thereof and application thereof in pharmacy | 河南师范大学 | 2021-03-30 | — | — | CN | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| CN-112204010-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | disclosed |
| WO-2020263660-A1 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE | MERCK SHARP & DOHME CORP. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2020188100-A2 | ROSCOVITINE ANALOGUES AND USE THEREOF FOR TREATING RARE BILIARY DISEASES | SORBONNE UNIVERSITE (FR) | 2020-09-24 | — | — | WO | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| CN-108358927-B | 1, 4-disubstituted 1,2, 3-triazole nucleoside analogue, and preparation method and application thereof | 郑州大学 | 2020-09-01 | — | — | CN | disclosed |
| CN-111606891-A | (1,1, 1-trichloro-2) carbamate derivative and preparation method and application thereof | 中南大学 | 2020-09-01 | — | — | CN | disclosed |
| EP-2844647-B1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-2844647-B1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10676720-B2 | Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, Nanog or c-Myc expression in fibroblasts | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2020-06-09 | — | — | US | disclosed |
| CN-106834176-B | Nucleoside phosphorylase, coding gene, high-yield strain thereof and application | 南京工业大学 | 2020-05-05 | — | — | CN | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| EP-3029041-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-10561661-B2 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-10561661-B2 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| WO-2019241896-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-12-26 | — | — | WO | disclosed |
| EP-2907514-B1 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2019-10-23 | — | — | EP | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190161738-A1 | COMBINATIONAL USE OF MECHANICAL MANIPULATION AND PROGRAMIN TO GENERATE PLURIPOTENT STEM CELLS FROM SOMATIC CELLS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-05-30 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10167451-B2 | Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, or Nanog expression in fibroblasts | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2018-12-20 | — | — | US | disclosed |
| US-20180360832-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2018-12-20 | — | — | US | disclosed |
| US-10130635-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2018-11-20 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| EP-2705029-B1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS S A (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | UNITED STATES DEPARTMENT OF ENERGY | 2018-09-13 | — | — | US | disclosed |
| EP-3150609-B1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | INTELLIKINE LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2857393-B1 | N-ARYL UNSATURATED FUSED RING TERTIARY AMINE COMPOUND, PREPARATION METHOD THEREOF AND ANTITUMOR APPLICATION THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-09-12 | — | — | EP | disclosed |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2991987-B1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| EP-2991987-B1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9975907-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2018-04-12 | — | — | US | disclosed |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2018-04-12 | — | — | US | disclosed |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2018-04-12 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-21 | — | — | US | disclosed |
| US-9751884-B2 | N-aryl unsaturated fused ring tertiary amine compounds, preparation method and anti-tumor applications thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-09-05 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3153514-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| CN-106188059-A | Some chemical entities, compositions and method | 英特利凯恩有限责任公司 | 2016-12-07 | — | — | CN | disclosed |
| US-9505762-B2 | Purine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505762-B2 | Purine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505762-B2 | Purine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9487772-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2918589-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-1881987-B1 | PURINE DERIVATIVES AND THEIR USE FOR TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC PHARMA SMT LTD (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-1881987-B1 | PURINE DERIVATIVES AND THEIR USE FOR TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC PHARMA SMT LTD (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-1761540-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2612862-B1 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9434746-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-9408848-B2 | Fluorescent CDK inhibitors for treatment of cancer | GEORGETOWN UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408848-B2 | Fluorescent CDK inhibitors for treatment of cancer | GEORGETOWN UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408848-B2 | Fluorescent CDK inhibitors for treatment of cancer | GEORGETOWN UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| CN-102711767-B | Certain chemical entities, compositions, and methods | 英特利凯恩有限责任公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20160177271-A1 | COMBINATIONAL USE OF MECHANICAL MANIPULATION AND PROGRAMIN TO GENERATE PLURIPOTENT STEM CELLS FROM SOMATIC CELLS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| EP-3029041-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS Corporation (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9334481-B2 | Compositions and methods for inducing cell dedifferentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-05-10 | — | — | US | disclosed |
| US-9309216-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9309216-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9309216-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2016-03-17 | — | — | US | disclosed |
| WO-2016034735-A1 | CHEMO-ENZYMATIC PREPARATION METHOD FOR PURINE NUCLEOSIDES AND THEIR DEAZA- AND AZA- ANALOGUES | Technische Universität Berlin (DE) | 2016-03-10 | — | — | WO | disclosed |
| EP-2993177-A1 | A chemo-enzymatic preparation method for purine nucleosides and their deaza- and aza- analogues | Technische Universität Berlin (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2991987-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2223922-B1 | Inhibitors of human phosphatidyl-inositol 3-kinase delta | ICOS CORP (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9206182-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206182-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9173938-B2 | Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| US-9149477-B2 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2918589-A1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | Intellikine, LLC (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2907514-A1 | Purine derivative compounds for medical use | Manros Therapeutics (FR) | 2015-08-19 | — | — | EP | disclosed |
| EP-2907514-A1 | Purine derivative compounds for medical use | Manros Therapeutics (FR) | 2015-08-19 | — | — | EP | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2448938-B9 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2015075598-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150141407-A1 | N-Aryl Unsaturated Fused Ring Tertiary Amine Compounds, Preparation Method and Anti-Tumor Applications Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2857393-A1 | N-ARYL UNSATURATED FUSED RING TERTIARY AMINE COMPOUND, PREPARATION METHOD THEREOF AND ANTITUMOR APPLICATION THEREOF | Institute Of Pharmacology And Toxicology Academy Of Militaty Medical Sciences P.L.A. (CN) | 2015-04-08 | — | — | EP | disclosed |
| US-8993583-B2 | 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-2456444-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8980901-B2 | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2844647-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | Rhizen Pharmaceuticals S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| EP-2845856-A1 | Pyrimidinones as PI3K inhibitors | Incyte Corporation (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140378479-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2014177490-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177490-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8785456-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785456-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8779131-B2 | 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140121223-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121224-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2705029-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Rhizen Pharmaceuticals S.A. (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8653077-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-02-18 | — | — | US | disclosed |
| US-8637533-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-8623881-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130345216-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-RE44638-E1 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| US-8586597-B2 | 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-11-19 | — | — | US | disclosed |
| US-RE44599-E1 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2013164801-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| CN-101240001-B | 2' -fluoro nucleosides | UNIV EMORY | 2013-10-16 | — | — | CN | disclosed |
| CN-101679434-B | 2, 6, 9-substituted purine derivatives having anti proliferative properties | CYCLACEL LTD | 2013-09-25 | — | — | CN | disclosed |
| US-20130231356-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2013-09-05 | — | — | US | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20130196989-A1 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2173173-B1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2013-07-24 | — | — | EP | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2612862-A2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | SCHINAZI RAYMOND F (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130116266-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| CN-102391356-B | Steroid n-glycoside analogue taking dihydro-pyranoid ring as D ring and preparation and application thereof | UNIV ZHENGZHOU | 2013-05-01 | — | — | CN | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-1682150-B1 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | SCRIPPS RESEARCH INST (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-8309555-B2 | Compositions and methods for inducing cell dedifferentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-13 | — | — | US | disclosed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| CN-102659785-A | 2-amino-6-aminomethylpurine compound and preparation method and application thereof | UNIV SHANDONG | 2012-09-12 | — | — | CN | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| CN-101678029-B | Purine-based CDK inhibitors in combination with tyrosine kinase inhibitors and their use in the treatment of proliferative diseases | CYCLACEL LTD | 2012-07-18 | — | — | CN | disclosed |
| CN-1440408-B | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP | 2012-07-18 | — | — | CN | disclosed |
| US-8222260-B2 | Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives | Univerzita Palackego V Olomouci (CZ) | 2012-07-17 | — | — | US | disclosed |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| US-8207153-B2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2456444-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Intellikine, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| CN-102482278-A | Pyrimidinones as PI3K inhibitors | INCYTE CORP | 2012-05-30 | — | — | CN | disclosed |
| US-8168583-B2 | 2-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
| CN-102391356-A | Steroid n-glycoside analogue taking dihydro-pyranoid ring as D ring and preparation and application thereof | UNIV ZHENGZHOU | 2012-03-28 | — | — | CN | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2396315-A1 | FUSED PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2011-12-21 | — | — | EP | disclosed |
| US-8080555-B2 | Purine derivatives and their use for treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| US-8080555-B2 | Purine derivatives and their use for treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| US-8080555-B2 | Purine derivatives and their use for treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| CN-101089010-B | 2' -fluoronucleosides | EMORY UNIVERSITY (US) | 2011-12-14 | — | — | CN | disclosed |
| EP-2392580-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2390257-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110269178-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269178-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269178-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110256952-A1 | GOLF CLUB, SHAFT REPLACING METHOD AND HEAD REPLACING METHOD | BRIDGESTONE SPORTS CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| CN-101031569-B | Quinazolinones as human phosphatidylinositol 3-kinase delta inhibitors | ICOS CORP | 2011-06-22 | — | — | CN | disclosed |
| EP-2330908-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | Georgetown University (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7951592-B2 | Compositions and methods for inducing cell dedifferentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7932260-B2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| EP-1278748-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1081148-B1 | Enantiomerically pure beta-D-dioxolane-nucleosides | UNIV GEORGIA (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2011008302-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| EP-1438052-B1 | QUINAZOLIN-4-ONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| CN-101862345-A | The modified nucleosides that is used for the treatment of viral infection and abnormal cell proliferation | PHARMASSET LTD | 2010-10-20 | — | — | CN | disclosed |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| EP-2223922-A2 | Inhibitors of human phosphatidyl-inositol 3-kinase delta | ICOS Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010092340-A1 | FUSED PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100173863-A1 | 2-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-08 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100143350-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2173173-A2 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-04-14 | — | — | EP | disclosed |
| CN-101679434-A | Has 2,6 of anti proliferative properties, the purine derivative that 9-replaces | CYCLACEL LTD | 2010-03-24 | — | — | CN | disclosed |
| CN-101678029-A | Purine-based CDK inhibitors in combination with tyrosine kinase inhibitors and their use in the treatment of proliferative diseases | CYCLACEL LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| WO-2010019967-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019967-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7662938-B2 | 2′-fluoronucleosides | EMORY UNIVERSITY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100022533-A1 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2139893-A2 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| CN-101622001-A | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases | IRM LLC | 2010-01-06 | — | — | CN | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-7592177-B2 | 2-(4-morpholinoanilino)-6-cyclohexylamino-purine; contacting a lineage committed cell (myoblast) with cell dedifferentiates into a multipotent stem cell; for repair of damaged tissues; cardiovascular, neurodegenerative disease and aging; small molecules | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-09-22 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20090042768-A1 | Purine derivatives and their use for treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042768-A1 | Purine derivatives and their use for treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042768-A1 | Purine derivatives and their use for treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2009003428-A2 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-01-08 | — | — | WO | disclosed |
| EP-2010533-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | Cyclacel Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| CN-100447143-C | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2008-12-31 | — | — | CN | disclosed |
| US-20080300398-A1 | 2'-FLUORONUCLEOSIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| CN-101240001-A | 2' -fluoro nucleosides | UNIV EMORY (US) | 2008-08-13 | — | — | CN | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
| EP-1939203-A2 | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform | ICOS Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1881987-A1 | PURINE DERIVATIVES AND THEIR USE FOR TREATMENT OF AUTOIMMUNE DISEASES | ProMetic BioSciences Inc. (CA) | 2008-01-30 | — | — | EP | disclosed |
| US-7321035-B2 | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-01-22 | — | — | US | disclosed |
| CN-101089010-A | 2' -fluoronucleosides | UNIV EMORY (US) | 2007-12-19 | — | — | CN | disclosed |
| US-7307065-B2 | 2′-Fluoronucleosides | EMORY UNIVERSITY (US) | 2007-12-11 | — | — | US | disclosed |
| CN-100349913-C | 2' -fluoro nucleosides | UNIV EMORY (US) | 2007-11-21 | — | — | CN | disclosed |
| US-20070254884-A1 | Compositions and Methods for Inducing Cell Dedifferentiation | THE SCRIPPS RESEARCH INSTITUTE | 2007-11-01 | — | — | US | disclosed |
| CN-100345552-C | Enantiomerically pure beta-d-dioxolane nucleosides with selective anti-hepatitus b virus activity | UNIV EMORY (US) | 2007-10-31 | — | — | CN | disclosed |
| CN-100343268-C | Beta-2 '-or 3' -halonucleosides | PHARMASSET LTD (BB) | 2007-10-17 | — | — | CN | disclosed |
| EP-1841769-A2 | PURINE DERIVATIVES COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AGAINST CANCER | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007110649-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | CYCLACEL LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110649-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | CYCLACEL LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| CN-1329393-C | New purine derivatives | CYCLACEL LTD (GB) | 2007-08-01 | — | — | CN | disclosed |
| EP-1682150-A4 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | SCRIPPS RESEARCH INST (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1375502-B1 | PROCESS FOR PRODUCING 2,6-DIHALOGENOPURINE | SUMITOMO CHEMICAL CO (JP) | 2007-06-13 | — | — | EP | disclosed |
| CN-1312152-C | Novel purine derivatives | CYCLACEL LTD (GB) | 2007-04-25 | — | — | CN | disclosed |
| EP-1761540-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1754710-A2 | 2'-Fluoroncucleosides | Emory University (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1529047-B1 | NEW PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006136005-A1 | PURINE DERIVATIVES AND THEIR USE FOR TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC BIOSCIENCES INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| EP-1244679-B1 | PURINE DERIVATIVES | ARIAD PHARMA INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1058686-B1 | 2'-FLUORONUCLEOSIDES | UNIV EMORY (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7115589-B2 | Purine derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| CN-1835952-A | 6-substituted anilinopurine as RTK inhibitors | IRM LLC (BM) | 2006-09-20 | — | — | CN | disclosed |
| WO-2006091905-A1 | BICYCLO (3.1.0) HEXANE DERIVATIVES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060183760-A1 | New purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-08-17 | — | — | US | disclosed |
| EP-1682150-A2 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | The Scripps Research Institute (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006075094-A2 | PURINE DERIVATIVES COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AGAINST CANCER | AVENTIS PHARMA S.A (FR) | 2006-07-20 | — | — | WO | disclosed |
| EP-1259520-B1 | NOVEL PURINES | ARIAD PHARMA INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1656378-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF RECEPTOR TYROSINE KINASE ACTIVITY | IRM LLC (BM) | 2006-05-17 | — | — | EP | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20060009642-A1 | Methods for the synthesis of substituted purines | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2006-01-12 | — | — | US | disclosed |
| WO-2005113554-A2 | METHOD OF PREPARING 3-PHENYL-2-[9H-PURIN-6-YLAMINO)-METHYL]-3H-QUINAZOLIN-4-ONE AND SUBSTITUTED AND RELATED COMPOUNDS | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| CN-1223594-C | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL CO (JP) | 2005-10-19 | — | — | CN | disclosed |
| CN-1679612-A | Enantiomerically pure beta-d-dioxolane nucleosides with selective anti-hepatitus b virus activity | UNIV EMORY (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1675213-A | Novel purine derivatives | CYCLACEL LTD (GB) | 2005-09-28 | — | — | CN | disclosed |
| CN-1675211-A | New purine derivatives | CYCLACEL LTD (GB) | 2005-09-28 | — | — | CN | disclosed |
| US-6949644-B2 | Methods for the synthesis of substituted purines | IRM LLC (BM) | 2005-09-27 | — | — | US | disclosed |
| US-6949522-B2 | β-2′- or 3′-halonucleosides | PHARMASSET, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-6949535-B2 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1529048-A4 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2005-09-14 | — | — | EP | disclosed |
| US-6936713-B2 | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20050176707-A1 | Compositions and methods for inducing cell dedifferentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| CN-1646141-A | Modified nucleosides for treating viral infections and abnormal cell proliferation | PHARMASSET LTD (BB) | 2005-07-27 | — | — | CN | disclosed |
| US-6911424-B2 | 2′-fluoronucleosides | EMORY UNIVERSITY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
| US-20050119286-A1 | BETA-2'-OR 3'-HALONUCLEOSIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-02 | — | — | US | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005047524-A2 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| EP-1529048-A2 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2005-05-11 | — | — | EP | disclosed |
| US-20050096298-A1 | Novel perines | METCALF CHESTER A III (US) | 2005-05-05 | — | — | US | disclosed |
| US-20050090666-A1 | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| CN-1195526-C | Pharmaceutical product containing enantiomerically pure beta-D-dioxolane nucleosides | UNIV EMORY (US) | 2005-04-06 | — | — | CN | disclosed |
| CN-1599744-A | Beta-2 '-or 3' -halonucleosides | PHARMASSET LTD (BB) | 2005-03-23 | — | — | CN | disclosed |
| WO-2005016528-A2 | 6-SUBSTITUTED ANILINO PURINES AS RTK INHIBITORS | IRM LLC (BM) | 2005-02-24 | — | — | WO | disclosed |
| US-20050026938-A1 | Purine inhibitors of protein kinases, G proteins and polymerases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA A CALIFORNIA CORPORATION (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | disclosed |
| EP-1478322-A2 | Beta-2'-OR 3'-HALONUCLEOSIDES | Pharmasset Limited (BB) | 2004-11-24 | — | — | EP | disclosed |
| US-6803371-B2 | FOR TREATING CELLULAR PROLIFERATIVE AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | disclosed |
| EP-1438052-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA | ICOS CORPORATION (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1418244-A1 | Exploiting genomics in the search for new drugs | Affymetrix, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| EP-1040204-B1 | EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS | AFFYMETRIX INC (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| EP-1375502-A1 | PROCESS FOR PRODUCING 2,6-DIHALOGENOPURINE | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6667300-B2 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION | 2003-12-23 | — | — | US | disclosed |
| CN-1460106-A | Process for preparing 2, 6-dihalogenopurine | SUMIKA FINE CHEMICALS CO LTD (JP) | 2003-12-03 | — | — | CN | disclosed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-20030180774-A1 | Exploiting genomics in the search for new drugs | AFFYMETRIX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030176699-A1 | Purine inhibitors of protein kinases, G proteins and polymerases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-18 | — | — | US | disclosed |
| US-20030171583-A1 | Methods for the synthesis of substituted purines | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2003-09-11 | — | — | US | disclosed |
| US-6617331-B2 | Inhibiting growth of a tumor cell | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-09 | — | — | US | disclosed |
| CN-1440408-A | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP (US) | 2003-09-03 | — | — | CN | disclosed |
| US-20030144508-A1 | Process for producing 2,6-dihalogenopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| US-20030114672-A1 | Purine inhibitors of protein kinases, G proteins and polymerases | GRAY NATHANAEL S (US) | 2003-06-19 | — | — | US | disclosed |
| US-6573044-B1 | Identifying compounds which modulate cell proliferation by comparing total number of mRNA transcripts from treated/untreated cells; use in drug screening and analyzing signal transduction pathways | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-03 | — | — | US | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003035075-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003031405-A2 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2003-04-17 | — | — | WO | disclosed |
| US-6524800-B2 | Genetic engineering; adjusting gene expression | AFFYMETRIX, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003000200-A2 | β-2'-OR 3'-HALONUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-01-03 | — | — | WO | disclosed |
| US-20020198171-A1 | 2'-fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| EP-1259520-A2 | NOVEL PURINES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
| EP-1246829-A1 | NOVEL HETEROCYCLES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1244679-A1 | PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020132819-A1 | Novel purinse | ARIAD PHARMACETICALS, INC. | 2002-09-19 | — | — | US | disclosed |
| US-20020103161-A1 | Novel heterocycles | ARIAD PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001044260-A9 | NOVEL PURINES | ARIAD PHARMA INC (US) | 2002-07-04 | — | — | WO | disclosed |
| US-20020068721-A1 | Purine derivatives | ARIAD PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | disclosed |
| US-6348587-B1 | PURINE OR PYRIMIDINE BASE DERIVATIVES; ANTICANCER, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS; TREATING HIV AND HEPATITIS | EMORY UNIVERSITY | 2002-02-19 | — | — | US | disclosed |
| CN-1332747-A | 2' -fluoro nucleosides | UNIV EMORY (US) | 2002-01-23 | — | — | CN | disclosed |
| US-20010055771-A1 | Exploiting genomics in the search for new drugs | AFFYMETRIX, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6333155-B1 | COMPARING DRUG VERSES MUTATION EFFECTS ON CELLS BY MEASURING THE INHIBITORY EFFECTS OF PURINE DERIVATIVES IN KINASE AND CELL GROWTH ASSAYS; DETERMINE THEIR EFFECTS ON MRNA LEVELS ON ALL YEAST GENES USING HIGH DENSITY OLIGONUCLEOTIDE EXPRESSION | AFFYMETRIX, INC. | 2001-12-25 | — | — | US | disclosed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6255485-B1 | PURINE ANALOGS THAT INHIBIT, INTER ALIA, PROTEIN KINASES, G-PROTEINS AND POLYMERASES; USEFUL IN TREATING CELLULAR PROLIFERATIVE DISEASES AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-07-03 | — | — | US | disclosed |
| WO-2001044260-A2 | NOVEL PURINES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044258-A1 | NOVEL HETEROCYCLES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044259-A1 | PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-0656778-B1 | ENANTIOMERICALLY PURE BETA-D-DIOXOLANE-NUCLEOSIDES | UNIV GEORGIA RES FOUND (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1081148-A2 | Enantiomerically pure beta-D-dioxolane-nucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1058686-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-1042509-A1 | METHODS OF USING OLIGONUCLEOTIDE ARRAYS TO SEARCH FOR NEW KINASE INHIBITORS | The Regents of the University of California (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1040204-A1 | EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS | Affymetrix, Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1003746-A1 | PURINE INHIBITOR OF PROTEIN KINASES, G PROTEINS AND POLYMERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999032660-A9 | EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS | AFFYMETRIX INC (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5925643-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 1999-07-20 | — | — | US | disclosed |
| CN-1044089-C | pharmaceutical composition with enantiomerically pure beta-D-dioxolane nucleosides as active ingredients | UNIV EMORY (US) | 1999-07-14 | — | — | CN | disclosed |
| WO-1999034018-A1 | METHODS OF USING CHEMICAL LIBRARIES TO SEARCH FOR NEW KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999032660-A1 | EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS | AFFYMETRIX (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007705-A1 | PURINE INHIBITOR OF PROTEIN KINASES, G PROTEINS AND POLYMERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5834474-A | Enantiomerically pure B--D--dioxolane nucleosides with selective anti-hepatitus B virus activity | EMORY UNIVERSITY (US) | 1998-11-10 | — | — | US | disclosed |
| US-5830898-A | Enantiomerically pure β-di-dioxolane-nucleosides with selective anti-hepatitis B virus activity | EMORY UNIVERSITY (US) | 1998-11-03 | — | — | US | disclosed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5767122-A | TREATMENT OF HIV INFECTIONS IN HUMANS | EMORY UNIVERSITY (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0666749-B1 | ENANTIOMERICALLY PURE beta-D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY | UNIV EMORY (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5684010-A | VIRICIDES | EMORY UNIVERSITY (US) | 1997-11-04 | — | — | US | disclosed |
| CN-1152435-A | Pharmaceutical product containing enantiomerically pure beta-D-dioxolane nucleosides | UNIV EMORY (US) | 1997-06-25 | — | — | CN | disclosed |
| US-5444063-A | 95% free of corresponding beta-L enantiomer; oral or parenteral administeration | EMORY UNIVERSITY (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0666749-A1 | ENANTIOMERICALLY PURE beta-D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0656778-A4 | ENANTIOMERICALLY PURE -g(b)-D-DIOXOLANE-NUCLEOSIDES. | UNIV GEORGIA (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0656778-A1 | ENANTIOMERICALLY PURE $g(b)-D-DIOXOLANE-NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| CN-1092427-A | Enantiomerically pure beta-D-dioxolane nucleosides with selective activity against hepatitis B virus | UNIV EMORY (US) | 1994-09-21 | — | — | CN | disclosed |
| EP-0270651-B1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INST OF TECHN (US) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994004154-A9 | ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDES | — | 1994-05-26 | — | — | WO | disclosed |
| WO-1994009793-A1 | ENANTIOMERICALLY PURE β-D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994004154-A1 | ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5118802-A | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5015733-A | Phosphoramidites and oligonucleotides derived therefrom | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1991-05-14 | — | — | US | disclosed |
| US-4849513-A | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012408-B2 | Purine compounds and method for the treatment of cancer | PNP, DPYD, NTPCR | CSNK2A1 2922/4885DPP4 3356/4885MAPT 4269/4885 |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CSNK2A1 1978/4885DPP4 1386/4885MAPT 4536/4885 |
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | CDK4, CDK3, CDKN1A | CSNK2A1 104/4885DPP4 3434/4885MAPT 3610/4885 |
| US-20020198171-A1 | 2'-fluoronucleosides | NSUN2, PNP, FDPS | CSNK2A1 3955/4885DPP4 1236/4885MAPT 4794/4885 |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | CSNK2A1 433/4885DPP4 3311/4885MAPT 2818/4885 |
| US-20090042768-A1 | Purine derivatives and their use for treatment of autoimmune diseases | PNP, XDH, SSB | CSNK2A1 4525/4885DPP4 2248/4885MAPT 4428/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | CSNK2A1 91/4885DPP4 2267/4885MAPT 1946/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 316/4885DPP4 2783/4885MAPT 4668/4885 |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | MSR1, TPMT, M6PR | CSNK2A1 4578/4885DPP4 2550/4885MAPT 4748/4885 |
| US-20070254884-A1 | Compositions and Methods for Inducing Cell Dedifferentiation | PAX3, PAX2, ALPG | CSNK2A1 2326/4885DPP4 2613/4885MAPT 4637/4885 |
| US-20060009642-A1 | Methods for the synthesis of substituted purines | PNP, ATIC, NUDT1 | CSNK2A1 4571/4885DPP4 2973/4885MAPT 2513/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | CSNK2A1 93/4885DPP4 4847/4885MAPT 4121/4885 |
| US-20220265637-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | CSNK2A1 364/4885DPP4 1248/4885MAPT 1903/4885 |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | TYMP, HPRT1, IMPDH1 | CSNK2A1 3707/4885DPP4 3191/4885MAPT 4400/4885 |
| US-20050176707-A1 | Compositions and methods for inducing cell dedifferentiation | PAX3, PAX2, ALPG | CSNK2A1 2326/4885DPP4 2613/4885MAPT 4637/4885 |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | CSNK2A1 3251/4885DPP4 1302/4885MAPT 2599/4885 |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CSNK2A1 1978/4885DPP4 1386/4885MAPT 4536/4885 |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 316/4885DPP4 2783/4885MAPT 4668/4885 |
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | CSNK2A1 484/4885DPP4 3165/4885MAPT 3351/4885 |
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | CSNK2A1 3955/4885DPP4 1236/4885MAPT 4794/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | CSNK2A1 364/4885DPP4 1248/4885MAPT 1903/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 316/4885DPP4 2783/4885MAPT 4668/4885 |
| US-20050119286-A1 | BETA-2'-OR 3'-HALONUCLEOSIDES | MKI67, EBP, PCNA | CSNK2A1 1812/4885DPP4 2948/4885MAPT 2559/4885 |
| US-20050096298-A1 | Novel perines | PNP, ENTPD5, NT5C2 | CSNK2A1 3873/4885DPP4 2238/4885MAPT 4798/4885 |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | CSNK2A1 426/4885DPP4 2936/4885MAPT 3286/4885 |
| US-20180360832-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 316/4885DPP4 2783/4885MAPT 4668/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | CSNK2A1 377/4885DPP4 1964/4885MAPT 2419/4885 |
| US-20130196989-A1 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | ALPG, PAX3, RARG | CSNK2A1 3229/4885DPP4 2080/4885MAPT 4677/4885 |
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | CSNK2A1 4798/4885DPP4 215/4885MAPT 3959/4885 |
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 316/4885DPP4 2783/4885MAPT 4668/4885 |
| US-20100093769-A1 | COMPOUNDS | CCR9, NPY1R, BCL9 | CSNK2A1 515/4885DPP4 2027/4885MAPT 2310/4885 |
| US-20050026938-A1 | Purine inhibitors of protein kinases, G proteins and polymerases | PNP, DTYMK, TYMP | CSNK2A1 835/4885DPP4 2791/4885MAPT 3802/4885 |
| US-20140121224-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYOSITOL 3-KINASE DELTA | PIK3CD, PIK3CB, PIK3CG | CSNK2A1 375/4885DPP4 3174/4885MAPT 4446/4885 |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 316/4885DPP4 2783/4885MAPT 4668/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | CSNK2A1 91/4885DPP4 2267/4885MAPT 1946/4885 |
| US-20100173863-A1 | 2-Fluoronucleosides | PNP, BCL3, NPC1 | CSNK2A1 4036/4885DPP4 1330/4885MAPT 4753/4885 |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CSNK2A1 113/4885DPP4 2555/4885MAPT 3090/4885 |
| US-20080300398-A1 | 2'-FLUORONUCLEOSIDES | METTL3, BCL3, PNP | CSNK2A1 3829/4885DPP4 1119/4885MAPT 4817/4885 |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | CSNK2A1 667/4885DPP4 453/4885MAPT 1748/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CSNK2A1 1978/4885DPP4 1386/4885MAPT 4536/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 363/4885DPP4 1830/4885MAPT 4869/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CSNK2A1 1978/4885DPP4 1386/4885MAPT 4536/4885 |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 371/4885DPP4 3138/4885MAPT 4583/4885 |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3R5, PIK3CA | CSNK2A1 401/4885DPP4 2602/4885MAPT 4727/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | CSNK2A1 442/4885DPP4 1960/4885MAPT 4789/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CSNK2A1 1978/4885DPP4 1386/4885MAPT 4536/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | CSNK2A1 3251/4885DPP4 1302/4885MAPT 2599/4885 |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CSNK2A1 1978/4885DPP4 1386/4885MAPT 4536/4885 |
| US-20210171524-A1 | PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | PNP, DPYD, NTPCR | CSNK2A1 2922/4885DPP4 3356/4885MAPT 4269/4885 |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | CSNK2A1 1672/4885DPP4 1026/4885MAPT 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.